Post Resch Tallon Group Inc. Purchases 64,920 Shares of Codexis, Inc. (NASDAQ:CDXS)

Post Resch Tallon Group Inc. boosted its holdings in Codexis, Inc. (NASDAQ:CDXS) by 16.1% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 468,587 shares of the biotechnology company’s stock after purchasing an additional 64,920 shares during the period. Codexis accounts for approximately 1.2% of Post Resch Tallon Group Inc.’s portfolio, making the stock its 25th largest position. Post Resch Tallon Group Inc.’s holdings in Codexis were worth $1,155,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Summit Investment Advisors Inc. raised its holdings in Codexis by 81.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,428 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 3,783 shares in the last quarter. Wolverine Trading LLC bought a new stake in shares of Codexis in the 4th quarter worth about $56,000. Fiduciary Trust Co bought a new stake in shares of Codexis in the 4th quarter worth about $65,000. Group One Trading LLC bought a new stake in Codexis during the fourth quarter worth about $73,000. Finally, ProShare Advisors LLC grew its stake in Codexis by 101.1% during the fourth quarter. ProShare Advisors LLC now owns 26,543 shares of the biotechnology company’s stock worth $127,000 after buying an additional 13,344 shares during the last quarter. Institutional investors own 78.54% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Codexis to a “sell” rating in a research report on Friday, May 16th.

Codexis Price Performance

Shares of CDXS stock opened at $2.29 on Monday. Codexis, Inc. has a 52 week low of $1.90 and a 52 week high of $6.08. The company has a debt-to-equity ratio of 0.59, a quick ratio of 3.64 and a current ratio of 3.72. The stock’s fifty day moving average is $2.34 and its 200-day moving average is $3.41. The stock has a market capitalization of $189.73 million, a PE ratio of -2.31 and a beta of 2.52.

Codexis (NASDAQ:CDXS) last released its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.05). Codexis had a negative net margin of 149.47% and a negative return on equity of 118.47%. The company had revenue of $7.54 million for the quarter, compared to the consensus estimate of $10.38 million. Equities research analysts expect that Codexis, Inc. will post -0.77 EPS for the current fiscal year.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.